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Abstract
Type 1 diabetes mellitus is a progressive disease caused by the destruction of pancreatic β-
cells, resulting in insulin dependency and hyperglycemia. While transplanted bonemarrow-
derivedmesenchymal stem/stromal cells (BMMSCs) have been explored as an alternative
therapeutic approach for diseases, the choice of delivery route may be a critical factor deter-
mining their sustainability. This study evaluated the effects of intrapancreatic and intrave-
nous injection of human BMMSCs (hBMMSCs) in streptozotocin (STZ)-induced type 1
diabetic mouse model. C57/BL6mice were intraperitoneally injected with 115mg/kg STZ on
day 0. hBMMSCs (1 × 106 cells) or vehicle were injected into the pancreas or jugular vein on
day 7. Intrapancreatic, but not intravenous, hBMMSC injection significantly reduced blood
glucose levels on day 28 compared with vehicle injection by the same route. This glucose-
lowering effect was not induced by intrapancreatic injection of human fibroblasts as the
xenograft control. Intrapancreatically injected fluorescence-labeled hBMMSCs were
observed in the intra- and extra-lobular spaces of the pancreas, and intravenously injected
cells were in the lung region, although the number of cells mostly decreased within 2 weeks
of injection. For hBMMSCs injected twice into the pancreatic region on days 7 and 28, the
injectedmice had further reduced blood glucose to borderline diabetic levels on day 56. Ani-
mals injected with hBMMSCs twice exhibited increases in the plasma insulin level, number
and size of islets, insulin-positive proportion of the total pancreas area, and intensity of insu-
lin staining compared with vehicle-injected animals. We found a decrease of Iba1-positive
cells in islets and an increase of CD206-positive cells in both the endocrine and exocrine
pancreas. The hBMMSC injection also reduced the number of CD40-positive cells merged
with glucagon immunoreactions in the islets. These results suggest that intrapancreatic
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injectionmay be a better delivery route of hBMMSCs for the treatment of type 1 diabetes
mellitus.
Introduction
Type 1 diabetes mellitus is a progressive disease caused by the destruction of pancreatic β-cells,
resulting in insulin dependency and hyperglycemia. Patients with the disease, who require
exogenous insulin treatment, are also at risk of blood glucose fluctuations and hypoglycemia.
Pancreas or pancreatic islet transplantation is a promising treatment for patients who lack
endogenous insulin secretion, particularly those who experience recurrent episodes of severe
hypoglycemia [1, 2]. However, the application of this approach is limited by a shortage of
organ donors and the need for lifelong administration of immunosuppressive agents, which
has potentially adverse effects [3±5].
Stem cell-based therapies have been explored as an alternative therapeutic approach for
type 1 diabetes mellitus because of the relatively high availability of stem cells [6]. Among the
various types of stem cells, mesenchymal stem/stromal cells (MSCs) are multipotent cells that
have the ability to differentiate into cells of mesodermal lineages, and their transplantation car-
ries a low risk of tumorigenesis and few ethical limitations [6±8]. MSCs can be isolated and
expanded with high efficiency from several adult and fetal tissues including bone marrow, adi-
pose tissue, dental pulp, and umbilical cord blood [9, 10]. MSCs have regenerative and immu-
nomodulatory properties after their transplantation into human patients and animal models
of diseases such as graft versus host disease, heart disease, Crohn's disease, and stroke [11, 12].
Currently, MSCs derived from human bone marrow (hBMMSCs) represent the most fre-
quently used type of MSC in clinical regenerative medicine [13, 14]. Carlsson et al. have
recently shown that hBMMSC transplantation preserves β-cell functions in patients with type
1 diabetes mellitus [15]. The cells were administered only once, intravenously, to these
patients. This treatment failed to decrease glycosylated hemoglobin concentrations, but pre-
vented the decreased C-peptide response to a mixed meal tolerance test at the 1 year follow-up
evaluation. Further improvements in treatment outcomes might be facilitated by a better
understanding of how hBMMSCs function and how they can be applied to treatment of type 1
diabetes mellitus.
Previous studies using animal models have revealed the importance of the delivery route
for MSC transplantation efficacy [16, 17]. In animal models, MSCs have been administered
intravenously. However, when MSCs were injected intravenously, most cells were trapped in
the lungs before reaching target tissues [18±21]. Intravenous hBMMSC transplantation has
also been evaluated in mouse models of type 1 diabetes mellitus in preparation for its clinical
application [22, 23]. Among such studies, Ho et al. demonstrated that a single intravenous
hBMMSC transplantation lowered blood glucose levels, but multiple transplantations at 2
week intervals were necessary to ensure the continuous maintenance of glucose homeostasis
[22]. Intra-arterial and local injections of MSCs, which could avoid lung entrapment of MSCs,
have been examined in animal models of diseases other than type 1 diabetes mellitus, com-
pared with their systemic injection [24±26]. In rats with traumatic brain injury, intra-arterial
transplantation of hBMMSCs leads to higher engraftment levels in the brain than intravenous
transplantation [24]. Furthermore, the advantage of local delivery of hBMMSCs into affected
joints compared with systemic delivery has been reported in rats with collagen-induced arthri-
tis [25]. These reports suggest that better delivery of the cells to target organs could provide
better therapeutic efficacy. We therefore investigated whether the effects of hBMMSCs on
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glucose homeostasis depend on the selected delivery route of intrapancreatic (local) or intrave-
nous (systemic) injection in an animal model of type 1 diabetes mellitus
Interestingly, in most experimental situations, MSCs exert therapeutic effects without evi-
dence of long-term engraftment because most transplanted cells disappear in a short time [18,
27, 28]. Recently, it has been demonstrated that MSCs play an important role as mediators of
inflammatory regulation [11, 29]. Accordingly, their beneficial effects are partly explained by
paracrine secretions or cell-to-cell contacts that have multiple effects including crosstalk
between MSCs and macrophages [28, 30±33]. Macrophages are classified into two major
types: pro-inflammatory (M1) and anti-inflammatory (M2) macrophages. M2 macrophages
are further classified into two subtypes: deactivated macrophages, which are induced by IL-10,
and alternatively activated macrophages that are induced by IL-4 [34, 35]. We previously
reported that local administration of hBMMSCs restores neural functions, increases alterna-
tively activated M2 macrophages in the hippocampus and spinal cord of mouse models of neu-
ral damage [27, 36], and decreases the number of M1 macrophages in vitro [37]. We suggest
that hBMMSCs facilitate restoration of neural functions by modulating the balance between
M1 and M2 macrophages.
Here, in the diabetic model induced by streptozotocin (STZ), we revealed that intrapan-
creatically hBMMSC-injected mice have greater improvements in glucose homeostasis and
body weights than intravenously hBMMSC-injected mice, along with cell retention in the pan-
creas. Intrapancreatically hBMMSC-injected mice have increased plasma insulin levels and
improved pancreatic islet histomorphology, suggesting that the injected cells might modify the
pancreatic macrophage state and decrease CD40-positive cells in islets.
Materials andmethods
Animals
Male 7±9-week-old C57/BL6 mice were purchased from Sankyo Lab Service (Tokyo, Japan)
and housed at constant temperature and humidity with a 12:12 hour light:dark cycle and ad
libitum access to a standard diet and water. All experimental procedures involving animals
were approved by the Institutional Animal Care and Use Committee of Showa University
(#04085, 05116, and 06012).
Measurement of blood glucose concentrations
Blood samples were obtained from the right facial vein of mice using an animal lancet (Gold-
enrod, MEDIpoint, Mineola, NY). Blood glucose concentrations were measured with a mini-
glucometer (MEDISAFE, Terumo, Tokyo, Japan) capable of measuring glucose concentrations
up to 600 mg/dL.
Preparation of hBMMSCs and adult human dermal fibroblasts (HDFs)
for injection
Frozen vials of human MSCs from adult bone marrow (hBMMSCs) were obtained from Dr.
Darwin J. Prockop of the Center for the Preparation and Distribution of Adult Stem Cells
(http://medicine.tamhsc.edu/irm/msc-distribution.html). This center functions under the aus-
pices of a National Institutes of Health (NIH)/National Center for Research Resources grant
(P40 RR 17447±06) and supplies standardized preparations of hBMMSCs enriched for early
progenitor cells. All experiments were performed with hBMMSCs from donor 281L. To
expand hBMMSCs, a frozen vial of 1 × 106 passage 3 cells was thawed, and the cells were cul-
tured in 20% complete culture medium (CCM) consisting of α-minimum essential medium
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(Invitrogen, Grand Island, NY) supplemented with 20% heat-inactivated fetal bovine serum
(FBS; HyClone, Thermo Fisher Scientific, Waltham,MA), 100 U/mL penicillin and 100 µg/mL
streptomycin (Pen/Str, Invitrogen), and 2 mM L-glutamine (Invitrogen). hBMMSCs were seeded
at 100 cells/cm2 in 20% CCM and incubated at 37ÊCin a humidified 5% CO2 atmosphere. The
medium was changed every 3±4days, and cells were grown to 70±80%confluency (approxi-
mately 8 days) [28]. The epitope profile of the cells showed that they were mostly positive for
CD29 (>92%), CD44 (>93%), CD90 (>99%), and CD105 (>99%), and negative for CD34
(<1.5%) and CD117 (<0.5%). A sample of hBMMSCs was labeled with fluorescent dyes NIR815
(Cell Vue NIR815 Cell Labeling Kit; Thermo Fisher Scientific, Waltham,MA) or PKH26
(PKH26 Red Fluorescent Cell Linker Kit; Sigma, St Louis, MO), as described previously [36].
HDFs isolated from adult human skin were human dermal fibroblasts and were obtained
from ScienCell Research Laboratories (Carlsbad, CA) and cultured in 10% Dulbecco's modi-
fied Eagle's medium (Invitrogen) with 10% FBS, Pen/Str, and 2 mM L-glutamine at 37ÊCin a
humidified atmosphere with 5% CO2 [37].
hBMMSCs and HDFs were harvested with 0.25% trypsin and 1 mM EDTA (Invitrogen),
and resuspended in sterile Hank's balanced salt solution (HBSS, Invitrogen) at 1 × 106 cells/
20 µL for intrapancreatic injection or 1 × 106 cells/150 µL for intravenous injection.
Table 1. Primary and secondary antibodies used for immunohistochemistry.
Primary Host Clone # Company Catalog # Dilution (fold)
α-amylase Rabbit Sigma Aldrich
(St. Louis, MO)
A8273 200
CD40 Armenian hamster (IgM) HM40-3 eBioscience
(San Diego, CA)
14±0402 2,000
CD206 Rat MR5D3 AbD Serotec
(Raleigh, NC)
MCA2235GA 500
F4/80 Rat CI:A3-1 BMA Biomedicals
(Augst, Switzerland)
T-2008 250
Glucagon Rabbit Sigma Aldrich SAB4501137 200
Iba-1 Rabbit Wako
(Osaka, Japan)
019±19741 500
Insulin Guinea pig Dako
(Glostrup, Denmark)
N1542 100
MHC class II Rat M5/114.15.2 eBioscience 14±5321 200
Secondary Host Conjugation Company Catalog # Dilution (fold)
Armenian hamster IgM Mouse Biotin BD Biosciences
(Franklin Lakes, NJ)
554035 200
FITC 554033 200
Guinea pig
IgG
Goat Biotin Vector Laboratories
(Burlingame, CA)
BA-7000 200
Alexa488 Thermo Fisher Scientific (Waltham, MA) A11073 500
Alexa546 A11074
Alexa647 A21450
Rabbit IgG Goat Biotin Vector Laboratories BA-1000 200
Alexa488 Thermo Fisher Scientific A11034 500
Alexa546 A11035
Alexa647 A21245
Rat IgG Goat Texas red Jackson Laboratories
(West Grove, PA)
112-075-167 200
FITC 112-095-167
CD40, cluster of differentiation 40; CD206, cluster of differentiation 206; FITC, fluorescein isothiocyanate; Iba1, ionized calcium-binding adapter molecule 1;
IgG, immunoglobulin G; IgM, immunoglobulin M; MHC, major histocompatibility complex
https://doi.org/10.1371/journal.pone.0186637.t001
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Induction of the diabetic model by STZ injection
Mice were fasted for 4 hours before STZ injection and then administered STZ (115 mg/kg,
Wako, Osaka, Japan) in saline by intraperitoneal injection on day 0. Blood glucose concentra-
tions and body weights were measured four times prior to the cell injection to confirm the
basal levels of glucose and development of STZ-induced diabetes mellitus: 7 and 3 days before,
and 5 and 7 days after STZ injection. Blood was sampled from the right facial vein between
9:00 am and 11:00 am. Drinking water was replaced with a 10% glucose solution (Otsuka,
Tokyo, Japan) overnight to avoid hypoglycemia in mice the day after STZ injection. Before cell
transplantation, mice with blood glucose concentrations between 220 and 500 mg/dL on days
5 and 7 were considered to have STZ-induced diabetes mellitus.
Cell transplantation
Diabetic mice were administered 3.5% sevoflurane in N2O/O2 (2:1) by inhalation for anesthe-
sia. For cell transplantation into the pancreatic region (intrapancreatic injection), the animals
were placed in the right lateral position, and an approximately 0.5 cm cut was made in the skin
and retroperitoneum to visually confirm the spleen. Twenty microliters of cell suspension
(1×106 cells) or vehicle were slowly injected into the pancreatic region adjacent to the spleen,
which consists of the tail of the pancreas, using an insulin syringe with a 29-G needle (Low
dose; BD Bioscience, San Jose, CA). Then, the animals were sutured to seal their skin and ret-
roperitoneum, and they recovered from the anesthesia. For intravenous injection, the animals
were placed in the supine position under anesthesia, and their skin and fascia on the right clav-
icle were incised. The right jugular vein was exposed, and 150 µL of cell suspension (1×106
cells) or vehicle was slowly injected into the vein (intravenous injection). The skin of the ani-
mals was sutured, and they recovered from the anesthesia.
Immunostaining
All primary and secondary antibodies used in the present study are listed in Table 1. Mice
were anesthetized by intraperitoneal injection of 50 mg/kg sodium pentobarbital and perfu-
sion-fixed with saline followed by 4% paraformaldehyde (PFA). The pancreas was then
removed and frozen sections were prepared (10 or 20 µm in thickness). The sections were
washed with phosphate buffered saline (PBS) and immersed in 0.3% H2O2 for 30 minutes to
quench endogenous peroxidases. The sections were then blocked by incubation with 2.5% nor-
mal horse serum (NHS; Vector Laboratories, Burlingame, CA) in PBS and incubated with pri-
mary antibodies against insulin, Iba-1, CD206, or CD40 overnight at 4ÊC.After washing with
PBS, the sections were incubated with appropriate biotinylated secondary antibodies for 2
hours. Binding was visualized using an avidin-biotin complex (ABC) solution (Vector Labora-
tories). For multiple staining, the pancreatic sections were blocked with 5% NHS and incu-
bated with several primary antibodies overnight at 4ÊC.The sections were washed, incubated
with appropriate fluorescence-labeled secondary antibodies for 2 hours, and then with 4,6-dia-
midine-2-phenylindole dihydrochloride (DAPI, 1:10,000; Roche, Manheim, Germany) to
identify cell nuclei.
We checked the specificity of the primary antibodies, using isotype controls. Isotype con-
trols are listed in following Table 2. Mice were anesthetized by intraperitoneal injection of 50
mg/kg sodium pentobarbital and perfusion-fixed with saline followed by 4% PFA. The pan-
creas was then removed and frozen sections were prepared (10 µm in thickness). The sections
were washed with PBS and immersed in 0.3% H2O2 for 30 minutes to quench endogenous per-
oxidases. The sections were then blocked by incubation with 2.5% NHS in PBS and incubated
with primary antibodies or isotype controls overnight at 4ÊC.The immunoglobulin content of
Intrapancreatic human bonemarrow-derivedmesenchymal stem/stromal cells alleviate hyperglycemia
PLOSONE | https://doi.org/10.1371/journal.pone.0186637 October 26, 2017 5 / 23
the isotype control except guinea pig immunoglobulin G (IgG) was equal to that of the primary
antibody which is the same host. Immunoglobulin concentration of anti-insulin antibody used
in this study was unavailable. The dilution rate of guinea pig IgG was equal to that of anti-insu-
lin antibody. After washing with PBS, the sections were incubated with appropriate biotiny-
lated secondary antibodies for 2 hours. Binding was visualized using an ABC solution.
Antibody specificity was confirmed by incubation of tissues in the absence of primary antibod-
ies and the presence of isotype controls (S1 Fig).
Experiment 1. Comparison of cell delivery routes in terms of blood
glucose and body weight
The choice of delivery route may be a critical factor determining the sustainability of
implanted MSCs. We first compared the effect of intrapancreatic and/or intravenous injec-
tions of hBMMSCs on blood glucose and body weight. On day 7 after STZ injection, the dia-
betic mice (n = 49) were divided into four experimental groups, vehicle-vein group (n = 13),
hBMMSC-vein group (n = 9), vehicle-pancreas group (n = 13), and hBMMSC-pancreas group
(n = 14), and administered the vehicle (HBSS) or a hBMMSC suspension intravenously into
the jugular vein (150 µL) or pancreatic region (20 µL) under 3.5% sevoflurane inhalation. The
blood glucose concentration and body weight of each mouse were measured on days 14, 21,
and 28.
Experiment 2. Effect of xenografts on blood glucose and body weight
In the present study, we injected human cells into mice. To rule out the xenograft as the cause
of glucose homeostasis, we compared the effects of intrapancreatic injections of hBMMSCs and
HDFs as the xenograft control. On day 7 after STZ injection, the mice (n = 36) were divided
into three groups, vehicle-pancreas group (n = 11), hBMMSC-pancreas group (n = 11), and
HDF-pancreas group (n = 14), and administered the vehicle (HBSS), a hBMMSC suspension,
or a HDF suspension into the pancreatic region (20 µL) under sevoflurane anesthesia. The
blood glucose concentration and body weight of each mouse were measured on days 14, 21,
and 28.
Experiment 3. Body and tissue distributions of hBMMSCs
In experiment 3, to compare the body distribution and fate of hBMMSCs resulting from intra-
pancreatic or intravenous injection into diabetic mice, we performed time-course in vivo fluo-
rescence imaging using NIR815-labeled hBMMSCs. We then examined the pancreatic tissue
distribution of cells using PKH26-labeled hBMMSCs with intrapancreatic injection.
Table 2. Isotype controls used for immunohistochemistry.
Isotype control Host Clone # Company Catalog #
Rabbit IgG Rabbit Wako 148±09551
Armenian
hamster IgM
Armenian hamster (IgM) HTK204 Bio Legend (San Diego, CA) 401005
Rat IgG Rat Wako 147±09521
Guinea pig IgG Guinea pig Medical Biological Laboratories
(Nagoya, Japan)
PM067
IgG, immunoglobulin G; IgM, immunoglobulin M
https://doi.org/10.1371/journal.pone.0186637.t002
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Body distribution of hBMMSCs analyzed by in vivo fluorescence imaging. NIR815 is a
membrane-binding fluorescent dye with excitation (Ex) at 633 nm and emission (Em) at 776
nm, which can be detected by an in vivo fluorescence imager (Clairvivo OPT; Shimadzu,
Kyoto, Japan). On day 6 after STZ injection, hair on the body trunk and forelimbs of mice was
removed using a depilatory cream (Epilat; Kracie, Tokyo, Japan). The next day, diabetic mice
(n = 24) were divided into four experimental groups, vehicle-vein group (n = 5), hBMMSC-
vein group (n = 8), vehicle-pancreas group (n = 3), and hBMMSC-pancreas group (n = 8), and
administered the vehicle (HBSS) or a NIR815-labeled hBMMSC suspension (1×106 cells) into
the jugular vein (150 µL) or pancreatic region (20 µL) under anesthesia induced by inhalation
of 2% isoflurane (Wako, Tokyo, Japan). Immediately after injection, the mice were placed in
the supine position on the stage of a fluorescence imager, and fluorescence intensities were
measured with an exposure time of 120 seconds. The same measurements were repeatedly per-
formed on days 8, 11, 14, 21, and 28 (1, 4, 7, 14, and 21 days after injection), and total fluores-
cence intensities were calculated in the left lateral abdomen under the subphrenic area,
corresponding to the pancreas, and in the right lateral supraphrenic area corresponding to the
right lung. Finally, the intensities were expressed after subtracting the mean fluorescence
intensities in mice injected with the vehicle via the same route. The right lung was selected for
analysis because fluorescence from the pancreatic area interfered with fluorescence from the
left lung in hBMMSC-pancreas animals.
Tissue distribution of hBMMSCs in intrapancreatic injection determined by histol-
ogy. The tissue distribution of hBMMSCs in the pancreas was examined by injecting
PKH26-labeled hBMMSCs into the pancreatic region. PKH26 is a membrane-binding fluores-
cent dye with Ex 551 and Em 567. The labeled cells were then detected by fluorescence micros-
copy. On day 7 after STZ injection, diabetic mice (n = 9) were administered a PKH26-labeled
hBMMSC suspension (1×106 cells) directly into the pancreas (20 µL) under sevoflurane anes-
thesia. On days 14, 21, and 28, the mice (n = 3 per day) were anesthetized by intraperitoneal
injection of 50 mg/kg sodium pentobarbital and perfusion-fixed with 0.9% saline followed by
4% PFA. Frozen sections (20 µm in thickness) were incubated with a primary antibody against
α-amylase, an exocrine pancreas marker, and DAPI (see Table 1). The stained sections were
then observed by confocal fluorescence microscopy (A1; Nikon, Tokyo, Japan).
Experiment 4. Effect of repeated hBMMSC injections
To further determine the effect of repeated intrapancreatic injections of hBMMSCs on blood
glucose, body weight, pancreatic histopathology, and plasma insulin levels, we injected
hBMMSCs twice into the pancreatic region on days 7 and 28.
On day 7 after STZ injection, diabetic mice (n = 23) were divided into two groups and
administered the vehicle (HBSS, n = 12) or hBMMSCs (n = 11) into the pancreatic region
(20 µL) under sevoflurane anesthesia. On day 28, both groups were again administered the
same treatment received on day 7. Blood glucose concentrations and body weights were mea-
sured on days 10, 14, 21, 28, 35, 42, 49, and 56.
Histological evaluation of the pancreas. On day 56, the animals (vehicle-pancreas group,
n = 5; hBMMSC-pancreas group, n = 5) were anesthetized with 50 mg/kg intraperitoneal
sodium pentobarbital and then perfused transcardially with 0.9% saline followed by 4% PFA.
Frozen pancreas sections were prepared at 10 µm in thickness. Pancreas sections were also
obtained from non-STZ-treated normal mice (untreated mice; n = 3) and at 7 days after STZ
injection (without hBMMSC injection; n = 4) by the same procedures.
Three sections from each mouse at 800 µm intervals were stained with hematoxylin and
eosin (H.E.) and photographed whole as an overview using a digital camera with macro mode
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(Ricoh CX4, Tokyo, Japan). The adjacent sections were stained with an anti-insulin primary
antibody as described below. Based on these sections, we determined the islet area, percentage
of the insulin-positive area, and islet number per area using Scion image software (NIH). In
brief, edges of the pancreas in the overview image were traced manually, and the total pancre-
atic area was calculated. The endocrine pancreas (i.e. the total area of insulin-positive clusters)
in each section was measured under an AX70 microscope (Olympus, Tokyo, Japan) at 20×
magnification with a DP2-BSW imager (Olympus), and the area of each pancreas was deter-
mined manually by circling each insulin-positive cluster. The insulin-positive area was auto-
matically calculated by binarizing the dark brown insulin-like immunoreactions in each
endocrine pancreas. The insulin-positive proportion of the total pancreas area in the sections
was calculated.
To determine the number of sections for histological evaluation, serial sections of the entire
pancreas from three untreated mice were prepared at intervals of 200 µm (nine sections). The
sections were stained with H.E. and an anti-insulin primary antibody. The area under the
curve (AUC) of the number of islets per pancreas area was estimated and compared between
different sectioning intervals: 200 (nine sections), 400 (five sections), and 800 (three sections)
µm. There were no differences in the AUCs among the intervals (S2 Fig). Therefore, we used
three sections at 800 µm intervals for histological evaluation.
Plasma insulin enzyme-linked immunosorbent assay (ELISA). On day 56, blood sam-
ples of the animals (vehicle-pancreas group, n = 8; hBMMSC-pancreas group, n = 8) were col-
lected from the right ventricle before perfusion fixation, and a heparinized plasma sample was
obtained to measure the plasma insulin concentration. Blood samples were also collected from
non-STZ-injected normal mice (n = 4) and on day 7 after STZ injection (without hBMMSC
injection; n = 3). Plasma insulin concentrations were determined using a mouse insulin ELISA
kit (Morinaga, Tokyo, Japan) according to the manufacturer's instructions.
Experiment 5. Effect of hBMMSCs onmacrophagemarkers
We have previously reported that hBMMSC injection into parenchyma of the brain and spine
improves injury and modifies the type of activated macrophage during ischemia and trauma
[27, 36, 37]. Therefore, we examined the effect of macrophage activation and phenotypes on
glucose homeostasis to investigate the possible mechanism of hBMMSCs.
On day 7 after STZ injection, diabetic mice (n = 12) were administered the vehicle (HBSS,
n = 6) or hBMMSCs (1×106 cells, n = 6) into the pancreatic region under sevoflurane anesthe-
sia and then sacrificed by 4% PFA perfusion fixation on day 28. Frozen pancreas sections were
prepared at 10 µm thicknesses for immunohistochemistry of macrophage markers. The sec-
tions were stained with anti-Iba1, anti-CD206, and anti-CD40 antibodies (see Table 1) with
colorimetric staining by the ABC system. Then, the number of positive cells was counted in
islets and exocrine areas (n = 5/animal), and the positive cell number in a certain islet or exo-
crine pancreas area was calculated by Scion image software. Simultaneously, we analyzed pan-
creatic sections from non-STZ-injected normal mice (n = 3). The sections were observed and
analyzed under the AX70 microscope at 20× magnification with the DP2-BSW imager.
Iba1- or CD40-positive cells were determined by multiple immunostaining for insulin (for
detection of islet), macrophage polarization markers, and glucagon. The sections were assessed
by visualization with the A1 confocal fluorescence microscopy system.
Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM). Statistical comparisons
were conducted using the Student's t-test for two groups, and one-way analysis of variance
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with non-parametric multiple comparisons for three or more groups, as indicated in each fig-
ure legend. A value of P< 0.05 was considered statistically significant.
Results
Determination of the optimal STZ dose and definition of the diabetic
model
We used mice with STZ-induced type 1 diabetes mellitus in the present study. However, the
optimal dose of STZ is quite different according to species and animal suppliers. Therefore, we
first determined the optimal STZ dose in C57/BL6 mice obtained from Sankyo Lab. We ini-
tially administered saline and STZ at doses of 100 (n = 3), 150 (n = 3), or 200 mg/kg body
weight (n = 3) to 8±10-week-oldmice via peritoneal injection (200 µL). The mean blood glu-
cose concentration of saline-injected mice was 172 ± 5 mg/dL (mean ± SEM, n = 7). All blood
glucose levels in 150 mg/kg or 200 mg/kg STZ-treated mice exceeded >600 mg/dL on day 5
whereas the levels in 100 mg/kg STZ-injected animals were no different from those in saline-
treated mice. Then, another group of C57BL/6 mice was administered STZ at doses of 115
(n = 8) or 130 mg/kg (n = 8), and blood glucose concentrations were determined on day 7.
While six of eight animals administered STZ at 130 mg/kg exceeded >600 mg/dL, animals
injected with 115 mg/kg STZ had mean blood glucose concentrations of 360 ± 46 and 390 ± 43
mg/dL (mean ± SEM, n = 8) on days 5 and 7, respectively, and only one animal exceeded
>600 mg/dL. Therefore, we determined that 115 mg/kg STZ was optimal for our study. We
finally decided to use diabetic mice with a blood glucose range from 220 to 500 mg/dL on days
5 and 7 for subsequent experiments.
Experiment 1
Effect of intrapancreatic and intravenous hBMMSC injections on blood glucose and
body weight in STZ-induced type 1 diabetic mice. The mean blood glucose concentration
of mice prior to STZ treatment was 169 ± 4 mg/dL (days −7 and −3), which increased to
317 ± 12 mg/dL on day 7 after STZ injection. To evaluate the effects of hBMMSCs on blood
glucose and body weight, hBMMSCs or the vehicle (HBSS) were administered to STZ-treated
mice via the pancreas or jugular vein. Blood glucose levels continued to increase following
intrapancreatic or intravenous injection of the vehicle, peaking at approximately 400 mg/dL
(Fig 1A and 1B). Although blood glucose levels tended to decrease following intravenous injec-
tion of hBMMSCs, the concentrations did not differ significantly from those in vehicle-treated
mice (Fig 1A). Intrapancreatic injection of hBMMSCs significantly reduced mean blood glu-
cose to 278 ± 27 mg/dL on day 14. This lower level of approximately 280 mg/dL was main-
tained until day 28 (Fig 1B). Body weights of mice injected with hBMMSCs into the pancreatic
region were significantly higher than those of mice injected with the vehicle on day 28, while
an insignificant difference was observed in the body weight between mice injected with
hBMMSCs into the vein and those injected with the vehicle into the vein (Fig 1C and 1D).
Experiment 2
Effects of intrapancreatic injection of hBMMSCs and HDFs on blood glucose and body
weight of STZ-induced type 1 diabetic mice. To determine whether the effects of
hBMMSCs were not due to xenoreactions on the part of mice against human cells, we com-
pared the effects of the vehicle, HDFs, and hBMMSCs injected into the pancreatic region of
STZ-treated mice. Diabetic animals injected with hBMMSCs had significantly decreased blood
glucose levels and increased body weights compared with those injected with the vehicle.
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However, HDF-injected animals exhibited similar blood glucose levels and body weights as
vehicle-injected mice and had significantly greater blood glucose and lower body weights than
hBMMSC-injected mice during the experimental periods (Fig 1E and 1F).
Experiment 3
Tracing of intrapancreatically and intravenously injected hBMMSCs. Previous studies
have reported that intravenously injected hBMMSCs are trapped in alveolar capillaries with
less distribution to peripheral tissues [18, 21, 38]. To compare the body distributions and fate
of hBMMSCs delivered by intrapancreatic or intravenous injection in diabetic mice, NIR815-
labeled hBMMSCs were injected via both routes, and fluorescence signals were tracked by an
in vivo fluoroimager in a time-dependent manner. Few fluorescence signals were detected in
mice injected with the vehicle into the pancreas and vein (data not shown). Following intrave-
nous cell injection on day 7, fluorescence signals were detected mainly in the chest region.
These signals clearly increased on day 8, suggesting that hBMMSCs had localized to the lungs.
The fluorescence signals gradually decreased and were hard to detect within a week of cell
injection, while they did not increase in other regions including the left lateral abdomen corre-
sponding to the pancreas. However, following intrapancreatic injection, fluorescence signals
were detected in the left lateral abdomen from day 7 with a dramatic increase on day 8, fol-
lowed by a gradual reduction until day 21 (Fig 2A). The fluorescence intensities in the right
Fig 1. Effects of hBMMSC injection on blood glucose and body weight of STZ-induced diabetic mice.Mice were injected intravenously (A,
C) or intrapancreatically (B, D) with hBMMSCs or the vehicle on day 7 after STZ treatment, and their blood glucose (A, B) and body weight (C, D)
were monitored until day 28. Mice were intrapancreatically injectedwith hBMMSCs, HDFs, or the vehicle on day 7 after STZ treatment, and their
blood glucose concentration (E) and body weight (F) were monitored until day 28. Data are expressed as themean ± SEM. *p < 0.05, **p < 0.01
(vs vehicle injection); #p < 0.05 (vs HDF injection) (Tukey post-hoc test).
https://doi.org/10.1371/journal.pone.0186637.g001
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supraphrenic chest and subphrenic left lateral abdomen were quantified in these mice. In the
right supraphrenic chest corresponding to the lung, signal intensities following intravenous
injection on days 8, 11, and 14 were greater than those following intrapancreatic injection. The
two groups subsequently exhibited similar signal intensities in this area from day 21 (Fig 2B).
Conversely, in the subphrenic left lateral abdomen corresponding to the pancreas, signal
intensities following intrapancreatic injection on days 8, 11, and 14 were significantly greater
than those following intravenous injection. The intensities were similar on day 21 onward and
declined over time (Fig 2C).
Pancreatic tissue distribution of intrapancreatically injected hBMMSCs. Having con-
firmed the distribution of hBMMSCs in the pancreas for intrapancreatic injection, we next
Fig 2. hBMMSC distribution following intrapancreatic or intravenous injection. Representative time-
course images of diabetic mice injectedwith NIR815-labeled hBMMSCs into the jugular vein or pancreatic
region (A) and semi-quantification graphs of the signal intensities in the right supraphrenic chest (B) and left
lateral abdomen under the subphrenic chest (C) (n = 8 per group). Data are expressed as the mean ± SEM.
*p < 0.05, **p < 0.01 (Student's t-test). (D) The injected PKH26-labeled hBMMSCs (red and arrows) were
located adjacent to the pancreas on day 14 (7 days after transplantation). Immunostaining of amylase, an
exocrine pancreaticmarker, is shown in green. Scale bars = 500 μm.
https://doi.org/10.1371/journal.pone.0186637.g002
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examined the tissue distribution of hBMMSCs after intrapancreatic injection by histochemis-
try using PKH26-labeled hBMMSCs. PKH26-labeled hBMMSCs were injected into the pan-
creatic region on day 7, and the red fluorescence signals were observed under a microscope on
day 14. A cluster of red fluorescence was detected in the region just outside of the positive area
for amylase, an exocrine pancreatic marker. Indeed, some red signals were also present in the
narrow interlobular spaces of the exocrine pancreas. However, few red signals were detected in
the pancreatic parenchyma (Fig 2D). We could not identify signals in islets (data not shown),
and signals could not be sufficiently observed after day 21.
Experiment 4
Effect of a second intrapancreatic injection of hBMMSCs on blood glucose and body
weight. Although a single intrapancreatic injection of hBMMSCs ameliorated hyperglyce-
mia, most injected hBMMSCs might disappear from the pancreas within 1 month. Therefore,
we investigated whether a second intrapancreatic injection of hBMMSCs could further amelio-
rate glucose homeostasis in mice with STZ-induced diabetes mellitus.
A second dose of cells was injected into the pancreas on day 28, and blood glucose and
body weight were monitored further until day 56. This second intrapancreatic injection of
hBMMSCs on day 28 further reduced the blood glucose concentration to 233 ± 26 mg/dL on
day 56, which was significantly lower than the level in vehicle-treated mice (416 ± 34 mg/dL;
Fig 3A). The second injection also further increased body weight on day 56 to 27.1 ± 0.4 g,
which was significantly higher than that of vehicle-injected mice (24.6 ± 0.3 g; Fig 3B).
Effect of a second intrapancreatic injection of hBMMSCs on plasma insulin and pancre-
atic histology. We then examined plasma insulin and pancreatic histology on day 56. Nor-
mal control mice (n = 4) had a mean plasma insulin concentration, measured by ELISA, of
996.5 ± 155.7 pg/mL, which was reduced to 499.7 ± 42.9 pg/mL on day 7 after STZ injection
(n = 3). On day 56, plasma insulin concentrations in mice intrapancreatically injected with
hBMMSCs (640.1 ± 85.7 pg/mL, p<0.05; n = 8) were significantly higher than those in mice
administered with the vehicle (385.8 ± 58.0 pg/mL, n = 8; Fig 4A).
hBMMSC-injected mice also had a higher pancreatic weight than vehicle-injected mice
(p<0.05; Fig 4B). H.E. staining of islets in normal control animals showed large round circles
that were strongly positive for immunostaining of insulin. The islets in mice treated with
hBMMSCs were larger than those in mice treated with the vehicle (Fig 4C). Seven days after
STZ injection, the size and insulin staining intensity of the islets were decreased by day 56, and
those of islets in the vehicle-treated mice had decreased further. However, in hBMMSC-treated
mice, the islets had increased in size by day 56 and exhibited an increase in insulin staining
intensity. On day 56, the islet area (2493 ± 362 µm2 vs 1343 ± 124 µm2, p<0.05), islet density
(0.440 ± 0.033 islets/mm2 vs 0.322 ± 0.027 islets/mm2, p<0.05), and insulin-positive area
(0.115 ± 0.023% vs 0.042 ± 0.002%, p<0.05) in mice intrapancreatically injected with
hBMMSCs were significantly higher than those in mice injected with the vehicle (n = 5 per
group; Fig 4D±4F).
Experiment 5
Effect of intrapancreatic injection of hBMMSCs on the macrophage state in STZ-
induced type 1 diabetic mice. It has been reported that hBMMSC transplantation has bene-
ficial effects on several types of tissue injury via modulations of the macrophage state [27, 31,
36, 39]. We therefore tried to investigate whether intrapancreatic hBMMSC injection influ-
enced the macrophage state.
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In STZ-untreated normal control mice, the pan-macrophage marker Iba1 was widely dis-
tributed in the islets and exocrine pancreas (Fig 5A and 5B). In vehicle-injected mice after STZ
treatment, an increase of the signal intensity for Iba1 immunoreactions was observed in the
islets and surrounding regions on day 28. These Iba1-positive cells exhibited macrophage-like
morphologies, such as large cell bodies and cytoplasmic processes, and some of them had an
activated state with large, round enlargement of the cytoplasm and short thick processes. How-
ever, intrapancreatic injection of hBMMSCs led to weak positive staining for Iba1 similar to
untreated control animals (Fig 5A and 5B).
Fig 3. A second intrapancreatic injection of hBMMSCs lowers the blood glucose concentration and
increases the body weight of STZ-induced diabetic mice. Effects of two hBMMSC injections into the
pancreatic region on blood glucose (A) and body weight (B) of STZ-treatedmice. The mice were injectedwith
hBMMSCs (n = 11) or the vehicle (n = 12) on days 7 and 28, andmonitored until day 56. Data are expressed
as the mean ± SEM. *p < 0.05, **p < 0.01 (Student's t-test).
https://doi.org/10.1371/journal.pone.0186637.g003
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The number of Iba1-positive cells was counted in islets and exocrine pancreases. The num-
ber of Iba1-positive islets in the vehicle-injected group was approximately 6- and 4-fold higher
than that in the STZ-untreated normal control group (p<0.01) and hBMMSC-injected group
(p<0.01), respectively (Fig 5C). No increase of the Iba1-positive number in the vehicle-
injected group was observed in the exocrine pancreas. However, the number in the hBMMSC-
injected group was 2-fold higher than that in vehicle-treated mice (p<0.01; Fig 5E).
Intrapancreatic injection of hBMMSCs increases CD206-positive macrophages. Exam-
ination of the number of Iba1-positive cells revealed opposing results in the region of islets
and the exocrine pancreas between vehicle- and hBMMSC-injected groups. We therefore per-
formed immunostaining of CD206, a marker of M2-type macrophage activation, in these mice
because we have reported that transplanted hBMMSCs increase this type of microglia/macro-
phage in neural damage and decrease inflammatory responses [27, 36]. A small amount of
CD206-positive cells was observed in the peri-islet area and exocrine pancreas of the untreated
group (Fig 5A and 5B). However, the numbers of CD206-positive cells in hBMMSC-injected
mice, both in the islets and exocrine pancreas, were significantly greater than those in either
the STZ-untreated control or vehicle-pancreas group (p<0.05, Fig 5D and 5F).
Pancreatic sections were then multi-stained to confirm the activation phenotype of Iba1-
positive cells. Cells positive for Iba1 in the islets of vehicle-injected mice were also positive for
F4/80, another pan-macrophage marker that is known to increase during inflammation (Fig
5G). Some Iba1-positive cells in mice injected with hBMMSCs were positive for CD206, sug-
gesting an M2 phenotype outside the islets (Fig 5H), as well as MHC class II (Fig 5I).
Fig 4. Effects of hBMMSCs on plasma insulin and pancreaticmorphology on day 56. Plasma insulin levels (A), pancreas weight (B), and
islet histologywith H.E. staining and insulin immunostaining (C) in mice intrapancreatically injected twice with hBMMSCs or the vehicle were
determined on day 56. Simultaneously, these parameters were determined in STZ-untreated control (untreated)mice on day 7 after STZ
treatment (STZ day 7 or STZ). Using histological sections, the islet area (D), insulin positive (+) area (E), and islet number (F) were
determined. Sample numbers are indicated in each bar. Data are expressed as the mean ± SEM and compared between vehicle- and
hBMMSC-injected groups on day 56 by the Student's t-test. Scale bars in (C) = 100 μm.
https://doi.org/10.1371/journal.pone.0186637.g004
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Intrapancreatic injection of hBMMSCs modifies the CD40-positive cell number. CD40
is a costimulatory protein found on antigen-presenting cells (APCs), including macrophages,
and is essential for dendritic cell activation [40]. CD40 is also expressed by non-immune cells
during inflammatory responses including those in diabetes [41±43]. Very weak and ambiguous
immunoreactivity was observed in STZ-untreated normal control mice (Fig 6A). For the vehi-
cle-injected group, the intensity and number of dark brown CD40 immunoreactions on day 28
were obviously increased in the islets, but not in the exocrine pancreases. In the hBMMSC-
injected group, on the other hand, immunoreactions were also recognized in the islets. CD40
immunoreactions were high in the marginal part of large islets (Fig 6A). The number of CD40
immunoreactions in the islets in the vehicle-injected group (16.6 ± 1.9 × 10−4 /µm2) was signifi-
cantly greater than that in STZ-untreated normal control group (3.0 ± 0.8 × 10−4/µm2) and that
in hBMMSC-pancreas group (6.5 ± 1.1 × 10−4/µm2, p<0.05) (Fig 6A and 6B). In contrast,
Fig 5. Intrapancreatic hBMMSC injection modulates themacrophage activation state.Representative
images of Iba1 and CD206 immunostaining in the islets (A) and exocrine pancreas (B) of STZ-untreated
control mice (untreated) and STZ-treatedmice on day 28 after intrapancreatic injection of hBMMSCs or the
vehicle. Scale bars = 100 μm. Semi-quantitative analysis of islets (C andD) and the exocrine pancreas (E and
F) for Iba1 (C and E) and CD206 (D and F) in untreated (n = 3), vehicle-treated (n = 6), and hBMMSC-treated
(n = 6) mice. Data are expressed as the mean ± SEM (Tukey post-hoc test). (G) Iba1 immunoreactions
(green) were mergedwith F4/80 (red) immunoreactions in the islets as indicated by insulin immunoreactions
(pink) in vehicle-injectedmice. (H) Iba1 immunoreactions (green) were mergedwith CD206 immunoreactions
(red) in the adjacent area of the islets (insulin immunoreactions; pink) in hBMMSC-injectedmice. (I) Iba1
immunoreactions (green) were mergedwith MHC class II (red) in the islets and adjacent in vehicle-injected
mice. DAPI staining (blue). Scale bars = 25 μm.
https://doi.org/10.1371/journal.pone.0186637.g005
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CD40-positive reactions in exocrine pancreases were very low and not different among the
groups (Fig 6A and 6C).
Multi-staining showed that CD40 immunoreactions did not colocalize with Iba-1, MHC
class II, or insulin immunoreactions (Fig 6D and 6E) or with positivity for B220 or CD11c
(data not shown). However, CD40 immunostaining clearly colocalized with glucagon immu-
noreactions (Fig 6F).
Discussion
Therapeutic approaches are needed to delay the progression of β-cell destruction and replace
lost insulin production in patients with type 1 diabetes mellitus. Therapies based on stem cells
such as MSCs have been explored as an alternative therapeutic approach for type 1 diabetes
mellitus and have beneficial effects in the animal model [22, 23, 44]. The choice of delivery
route may be a critical factor determining the sustainability of implanted MSCs. Therefore, in
this study, we compared the effects of hBMMSCs by intrapancreatic (local) and intravenous
(systemic) injections on STZ-induced diabetic mice. Intrapancreatic injection of the cells sig-
nificantly lowered the blood glucose concentration and increased body weight, whereas the
effects of intravenous injection on these parameters were insignificant. Because intrapancreati-
cally injected HDFs as a xenograft control could not reproduce the beneficial effects of
hBMMSCs, the effects were specific and not nonspecific xenograft responses to hBMMSCs.
Intrapancreatically injected hBMMSCs showed greater retention in the pancreas than
Fig 6. Intrapancreatic hBMMSC injection reducesCD40 immunoreactivity in islets.Representative images (A)
and semi-quantification of CD40 immunostaining in the islets (B) and exocrine pancreases (C) of STZ-untreated
control mice (n = 3; untreated) andmice intrapancreatically injected with the vehicle or hBMMSCs (n = 6 per group).
Scale bars = 50 μm. Data are expressed as the mean ± SEM. (Tukey post-hoc test). (D) CD40 immunoreactions
(green) were observed inside of the islet (insulin immunostaining; yellow), indicated by a dashed circle, and were not
merged with Iba1 immunoreactions (red) in vehicle-injectedmice. (E) CD40 immunoreactions (green and arrow)
mainly localized to themarginal area of the larger islet and were not merged with MHC class II (red and arrowhead) or
insulin (yellow) in hBMMSC-injectedmice. (F) CD40 immunoreactions (green) in vehicle-injected mice were found in
the islet and weremerged with glucagon (red) immunoreactions, indicated by arrows, but not insulin (pink)
immunoreactions. DAPI staining (blue). Scale bars = 25 μm.
https://doi.org/10.1371/journal.pone.0186637.g006
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intravenously injected hBMMSCs, although most cells, even in the former group, decreased
within 2 weeks of the injection. These results suggest that the effect of hBMMSCs might be
closely associated with local delivery. In this study, hBMMSCs were injected into the pancre-
atic region by opening the abdomen. Such an invasive procedure is not suitable for human
therapy. Clinically, however, pancreatic cancer has been treated by gastric fiber-guided intra-
pancreatic injection of chemotherapeutic agents [45, 46], which suggests that intrapancreatic
transplantation of hBMMSCs could be possible in patients with type 1 diabetes mellitus. Taken
together with the findings of the current study, it suggests that cell transplantation into the
pancreas might be a feasible novel therapeutic strategy.
Although a single hBMMSC injection into the pancreatic region significantly decreased the
blood glucose concentration in STZ-induced diabetic mice, the concentration was approxi-
mately 2-fold higher in non-diabetic mice, and most hBMMSCs had disappeared from the
pancreas. Therefore, we performed a second hBMMSC injection into the pancreatic region on
day 28 and found a further decrease in the blood glucose concentration to borderline diabetic
levels on day 56. hBMMSCs injected into the pancreas significantly increased the body weight
of the animal. Clinically, compared with healthy individuals, type 1 diabetic mellitus patients
usually have lower body weight with an insulin deficiency induced by hyperglycemia and
higher energy consumption of fat and muscles [47, 48]. Although we did not examine the fat
pad mass or glucose tolerance, the increase in body weight might reflect an improvement of
diabetic symptoms.
It has been reported that diabetic symptoms improve by suppression of immune responses
[23, 49], anti-inflammation [50±54], and enhancing β-cell or insulin-secreting cell regenera-
tion [55, 56] and angiogenesis [53, 54]. Moreover, an increase of α-cells or glucagon-secreting
cells in damaged islets might be a negative factor in diabetes [57, 58]. hBMMSCs have been
reported to differentiate into β-cells [22, 59], support pancreatic progenitor cell proliferation
[60], suppress immune/inflammatory responses [23, 59], and increase angiogenesis [60].
Under inflammatory conditions, hBMMSCs modulate the state of macrophage-lineage cells
by cell-cell communication, resulting in anti-inflammation [27, 31, 36, 37]. We have reported
that local hBMMSC injection increases the macrophage anti-inflammatory M2 subtype during
brain ischemia and spinal cord injury, suggesting that hBMMSCs decrease neural damage [27,
36]. We therefore confirmed the effect of hBMMSCs on the macrophage state in the STZ-
induced diabetic model. We determined that intrapancreatically injected hBMMSCs influ-
enced the macrophage number and activation state in islets and exocrine pancreases by pan-
macrophage marker Iba1 and a M2 subtype marker, CD206. Mice injected with hBMMSCs
had a decrease in the Iba1-positive cell number of islets, but increased CD206-positive cells in
both islets and the exocrine pancreas. Iba1-positive cells in the islets of mice injected with vehi-
cle also exhibited thick cytoplasmic processes and large cell bodies, and partially colocalized
with F4/80. While F4/80 is another pan-macrophage marker, its expression increases accord-
ing to macrophage M1 activation. CD206 is a subtype marker of alternatively activated M2
macrophages which is induced by IL-4, and contributes to tissue resolution and repair [35].
We have reported that transplanted hBMMSCs increase IL-4 and induce this subtype of mac-
rophage after CNS diseases [27, 36]. The alternative activated M2 macrophages were recruited
to the pancreas in experimental models to promote β-cell survival [53±55]. These findings sug-
gest that hBMMSCs contributed to the resolution of the islets.
We also found that the signal intensity and number of CD40-positive cells were increased
in islets by STZ treatment, and that this density of CD40 in islets was decreased significantly
by hBMMSC injection. CD40, a glycoprotein belonging to the tumor necrosis factor receptor
superfamily, is a costimulatory protein that is expressed on APCs, including dendritic cells,
activated macrophages, and mature B cells, and contributes to autoimmunity [41, 49]. CD40±
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CD40 ligand (CD154) signaling has been found to enhance vascular inflammation [61], bowel
disease [62], and nephropathy [63]. CD154 treatment increases the levels of inflammatory
cytokines in cultured β-cells [64], whereas treatment with an anti-CD154 antibody decreases
blood glucose and increases pancreas allograft engraftment [65, 66]. Although we initially
expected to observe CD40 expression in macrophages and/or APCs, few CD40-positive cells
expressed APC or macrophage markers. CD40 has been reported to be expressed by non-
immune cells [41±43, 67±69]. For example, CD40 is expressed in retinal endothelial cells and
MuÈller cells [70], as well as in islet β-cells [43] during hyperglycemia. In this study, we observed
CD40 in the peripheral area of the islets, mostly in glucagon-positive α-cells. Recently,
increases in glucagon and/or the number of α-cells were reported to be essential to elevate
blood glucose levels [71]. Blood glucose does not increase in mice with α-cell degeneration
caused by conditional deletion of the X-linked aristaless-related homeobox gene, even when β-
cells are disrupted by STZ injection [57]. Moreover, normal blood glucose levels are observed
in glucagon receptor gene-deficient mice [58]. We found that the CD40-positive area, which
overlapped with α-cells, was increased after STZ treatment and reduced by intrapancreatic
injection of hBMMSCs. Taken together, these findings suggest that the reduction in CD40,
overlapped with glucagon-positive reactions caused by hBMMSC injection might be associated
with glucose homeostasis. Further studies are needed to determine the role of CD40 in α-cells
and the mechanism by which hBMMSCs suppress glucagon levels and/or reduce the α-cell
number.
In the present study, we did not show that hBMMSCs increased regeneration of the islets. It
is not likely that transplanted hBMMSCs actively differentiated into β-cells because we could
not find PKH26-labeled hBMMSCs in the islets. However, on day 56 of experiment 4,
hBMMSC-injected animals had an improved plasma insulin level, pancreas weight, and histo-
morphological level of islets including the number, size, and insulin immunoreactions com-
pared with vehicle-injected mice. The plasma insulin level, pancreas weight, and
histomorphological level of islets in hBMMSC-injected animals on day 56 also tended to be
greater than those in animals on day 7 before STZ injection, but the difference was insignifi-
cant. Further studies need to demonstrate the role of hBMMSCs, including pancreatic degen-
eration and/or regeneration in the future.
A future study should demonstrate a direct causal link between the modulation of pancre-
atic inflammation/immune responses including macrophage polarization and/or CD40-posi-
tive glucagon cells and the glucose-lowering effect of intrapancreatic hBMMSC injection.
Because the STZ-induced diabetes model might not model human type 1 diabetes, we would
also like to evaluate the effects of intrapancreatic hBMMSC injection in other animal models
of type 1 diabetes such as non-obese diabetic mice, and the interactions between hBMMSCs
and immune cells in vitro.
Conclusions
In the present study, we demonstrated that intrapancreatic injection of hBMMSCs prevents
hyperglycemia and restores body weight compared with intravenous injection into STZ-
induced diabetic mice. Although the injected hBMMSCs disappeared from the pancreas
within a month, the hBMMSCs improved plasma insulin levels and the islet morphohistology.
Moreover, we confirmed that mice injected with hBMMSCs into the pancreas had a modu-
lated macrophage number and activation state, and the decrease in the number of CD40-posi-
tive cells overlapped with glucagon in islets. Taken together, these findings suggest that
intrapancreatic hBMMSCs injection might be an alternative therapeutic approach to restore β-
cell functions in type 1 diabetes mellitus.
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Supporting information
S1 Fig. Specificity of primary antibodies. Representative images of amylase immunostaining
in the exocrine pancreas and glucagon in the islet of STZ-untreated control mice and Iba1
immunostaining in the islets of STZ-treated mice on day 7 compared with Rabbit IgG and the
absence of primary antibodies (1st antibodies free). Representative images of F4/80, CD206,
and MHCⅡ immunostaining in the islet of STZ-treated mice on day 7 compared with Rat IgG
and 1st antibodies free. Representative images of CD40 immunostaining in the islet of STZ-
treated mice on day 7 compared with Armenian hamster IgM and 1st antibodies free. Repre-
sentative images of insulin immunostaining in the islet of STZ-untreated control mice com-
pared with Guinea pig IgG and 1st antibodies free. Scale bar is 200 µm.
(TIF)
S2 Fig. Determination of the number of sections for histological evaluation of pancreases.
Pancreatic sections from non-diabetic mice were collected at intervals of 200 µm (nine sec-
tions). The sections were stained with hematoxylin-eosin and an antibody against insulin. The
islet number was determined in the sections at 200 µm (nine sections). 400 µm (five sections),
and 800 µm (three sections) intervals. The islet number of per unit area in each analysis and
the calculated area under the curve (AUC). The results suggested that analysis of three sections
at 800 µm intervals was appropriate in this study for histological evaluation.
(TIF)
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